BiotechTV

Daily biotech news, content, and exclusive interviews.

[BiotechTV @BiotechTV]

𝐇𝐒𝐁𝐂 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐁𝐚𝐧𝐤𝐢𝐧𝐠: Star Therapeutics is a biotech discovering and developing novel medicines.

@HSBCInnovation provides them with tailored financial solutions designed to meet their capital needs and help unlock growth at each stage.

[BiotechTV @BiotechTV]

Will AI cure all diseases over the next decade? We asked @BenjamineYLiu.

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @formationbio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - a step in its plan to make drug development more efficient and become 'the next pharma'. @BenjamineYLiu

Watch the full video: https://t.co/saIFFtiJuI

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @Mizuho Senior Biotech Analyst @soowannaway gives his take on biotech's pause and discusses companies he covers with key items in the news.

$BLTE $TARS $ALKS $PVLA $CRVS

Full video: https://t.co/iPMe8JUDXz

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @ZentalisP aims to deliver to the ovarian cancer community a precision medicine approach - a targeted (WEE1) oral therapy for patients who are Cyclin E1 positive. $ZNTL

Full video: https://t.co/364zlfa3yY

[BiotechTV @BiotechTV]

𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞 𝟐𝟎𝟐𝟔: Bionyra emerged from stealth earlier this year with $165m in series A financing and three in-licensed assets: a TL1A Mab, a TL1A*IL-23p19 bispecific, and an IL-25 Mab.

Full video: https://t.co/6L9LRzimxK

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: Biotech has been affected like many sectors by the overall macro picture lately. @NYSE Market Strategist @Eric_Criscuolo breaks it down.

[BiotechTV @BiotechTV]

𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞 𝟐𝟎𝟐𝟔: Abalos Therapeutics GmbH will have p1 data on its lead project in 1H27, a non-oncolytic arenavirus-based product that is being tested in refractory/relapsed solid tumors.

Full video: https://t.co/KLXT5RcL9A

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: @TraceNeuro believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors.

Full video: https://t.co/VCYB2CFO8H

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: Oruka Therapeutics' IL-23p19 is showing strong efficacy in p2 psoriasis studies compared to existing products and might be dosed as little as once or twice a year - a key update will read next month. $ORKA

Full video: https://t.co/UA2snXwjIx

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: Here's why @Stifel's @TimOpler expects 2027 to be a 'blowout year' for big pharma M&A.

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: @Stifel's @TimOpler on the state of biotech.

Full video: https://t.co/sjc0okVkNU

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: @ProMISinc has an early, yet important Alzheimer's trial scheduled to read out over the coming months. $PMN

Full video: https://t.co/1PzVqTS0mt

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: With expertise in the next generation of GPCR development, @Septerna_Inc will have initial human data on its oral PTH1R agonist for hypoparathyroidism in Q1. $SEPN

Full video: https://t.co/QgYckw3ahy

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: Rapport Therapeutics CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead. $RAPP

Full video: https://t.co/hbUWLNRGBo

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: @Stifel's Head of Global Equity Capital Markets Seth Rubin shares his take on the state of biotech and the current environment for companies to raise money.

Full video: https://t.co/2XIQwxLusN

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: @REGENXBIO will have its pivotal studies for wet AMD read out before the end of the year - combined, they are the largest study of a gene therapy ever. $RGNX

Full video: https://t.co/hrCAUgYphY

[BiotechTV @BiotechTV]

𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞 𝟐𝟎𝟐𝟔: CEO Alan Barge describes 4C Biomed's lead asset, which acts against a novel checkpoint target, 4CB1.

Full video: https://t.co/ujXIhIuhtV

[BiotechTV @BiotechTV]

𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞 𝟐𝟎𝟐𝟔: Epitopea has just started dosing patients in the first clinical trial of its RNA-based cancer vaccine.

Full video: https://t.co/GpdXj3Odr1

[BiotechTV @BiotechTV]

𝐒𝐓𝐈𝐅𝐄𝐋 𝟐𝟎𝟐𝟔: @CompugenLtd has a trial in ovarian cancer for its PVRIG scheduled to read out in the early part of 2027 - later that year brings the start of Astra's big readouts with the TIGIT bispecific. $CGEN

Full video: https://t.co/TXG4kmtP4j